Evidence map›Paper›PMID 30217299›Full record

ArticleSurgical oncology2018

Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.

Koji Matsuo, Yutaka Takazawa, Malcolm S Ross, Esther Elishaev, Mayu Yunokawa, Todd B Sheridan, Stephen H Bush, Merieme M Klobocista, Erin A Blake, Tadao Takano and 39 more

Open access · greenAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Endometrial carcinosarcoma without myoinvasion.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Uterine carcinosarcoma: Unraveling the role of epithelial-to-mesenchymal transition in progression and therapeutic potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors at 20 institutions in 2 countries.

Koji MatsuoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA. Electronic address: koji.matsuo@med.usc.edu.
Yutaka TakazawaDepartment of Pathology, Cancer Institute Hospital, Tokyo, Japan.
Malcolm S RossDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, MaGee-Womens Hospital, University of Pittsburgh, USA.
Esther ElishaevDepartment of Pathology, MaGee-Womens Hospital, University of Pittsburgh, USA.
Mayu YunokawaDepartment of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Todd B SheridanDepartment of Pathology, Mercy Medical Center, Baltimore, USA.
Stephen H BushDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, USA.
Merieme M KlobocistaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, USA.
Erin A BlakeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, USA.
Tadao TakanoDepartment of Obstetrics and Gynecology, Tohoku University, Miyagi, Japan.
Tsukasa BabaDepartment of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan.
Shinya SatohDepartment of Obstetrics and Gynecology, Tottori University, Tottori, Japan.
Masako ShidaDepartment of Obstetrics and Gynecology, Tokai University, Kanagawa, Japan.
Yuji IkedaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Sosuke AdachiDepartment of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
Takuhei YokoyamaDepartment of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka, Japan.
Munetaka TakekumaDepartment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Shiori YanaiDepartment of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama, Japan.
Satoshi TakeuchiDepartment of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan.
Masato NishimuraDepartment of Obstetrics and Gynecology, Tokushima University, Tokushima, Japan.
Keita IwasakiDepartment of Obstetrics and Gynecology, Aichi Medical University, Aichi, Japan.
Marian S JohnsonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, USA.
Masayuki YoshidaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Ardeshir HakamDepartment of Pathology, Moffitt Cancer Center, University of South Florida, USA.
Hiroko MachidaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA.
Paulette Mhawech-FaucegliaDepartment of Pathology, University of Southern California, Los Angeles, USA.
Yutaka UedaDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Kiyoshi YoshinoDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Hiroshi KajiwaraDepartment of Pathology, Tokai University, Kanagawa, Japan.
Kosei HasegawaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Masanori YasudaDepartment of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.
Takahito M MiyakeDepartment of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.
Takuya MoriyaDepartment of Pathology, Kawasaki Medical School, Okayama, Japan.
Yoshiaki YubaDepartment of Pathology, Kitano Hospital, Osaka, Japan.
Terry MorganDepartment of Pathology, Oregon Health & Science University, USA.
Tomoyuki FukagawaDepartment of Pathology, Iwate Medical University, Morioka, Japan.
Tanja PejovicDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health & Science University, USA.
Tadayoshi NaganoDepartment of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.
Takeshi SasakiDepartment of Pathology, The University of Tokyo, Tokyo, Japan.
Abby M RichmondDepartment of Pathology, University of Colorado, USA.
Miriam D PostDepartment of Pathology, University of Colorado, USA.
Mian M K ShahzadDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, USA.
Dwight D ImDepartment of Gynecology, Mercy Medical Center, Baltimore, USA.
Hiroshi YoshidaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Kohei OmatsuDepartment of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Frederick R UelandDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, USA.
Joseph L KelleyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, MaGee-Womens Hospital, University of Pittsburgh, USA.
Rouzan G KarabakhtsianDepartment of Pathology, University of Kentucky, USA; Department of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, USA.
Lynda D RomanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA.
University of Southern California · USGynecologic Oncology Group · USThe Cancer Institute Hospital · JPUniversity of Colorado Boulder · USUniversity of Pittsburgh · USAlbert Einstein College of Medicine · USIwate Medical University · JPKawasaki Medical School · JPKitano Hospital · JPMercy Medical Center · USThe University of Tokyo · JPTokai University · JPTokyo National Hospital · JPUniversity of South Florida · USAichi Medical University · JPKurashiki Medical Center · JPKyoto University · JPMoffitt Cancer Center · USNiigata University · JPOregon Health & Science University · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CARYN LERMAN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

objectiveTo examine significance of sarcoma dominance (SD) patterns in uterine carcinosarcoma (UCS).

methodsThis is a secondary analysis of multicenter retrospective study examining women with stages I-IV UCS who underwent primary surgery. SD was defined as >50% of sarcoma component in uterine tumor. SD patterns were grouped as homologous sarcoma without SD (homo/non-dominance, n = 351), heterologous sarcoma without SD (hetero/non-dominance, n = 174), homologous sarcoma with SD (homo/dominance, n = 175), and heterologous sarcoma with SD (hetero/dominance, n = 189), and correlated to tumor characteristics and survival.

resultsSD patterns were significantly associated with age, body habitus, carcinoma type, tumor size, depth of myometrial invasion, and nodal metastasis (all, P < 0.05). On univariate analysis, SD was associated with decreased progression-free survival (PFS) and cause-specific survival (CSS) in homologous cases (both, P < 0.05) but not in heterologous cases. On multivariate models, both homologous and heterologous SD patterns remained independent prognostic factors for decreased PFS (adjusted-hazard ratio [HR] ranges: homo/dominance 1.35-1.69, and hetero/dominance 1.47-1.64) and CSS (adjusted-HR ranges: 1.52-1.84 and 1.66-1.81, respectively) compared to homo/non-dominance (all, P < 0.05). Among stage I-III disease, when tumors had SD, adding radiotherapy to chemotherapy was significantly associated with improved PFS (adjusted-HR: homo/dominance 0.49, and hetero/dominance 0.45) and CSS (0.36 and 0.31, respectively) compared to chemotherapy alone (all, P < 0.05); contrary, this association was not observed with absence of SD (all, P > 0.05).

conclusionIn UCS, SD impacts survival in homologous but not in heterologous type. Regardless of sarcoma types, SD was associated with decreased survival in UCS; adding radiotherapy to chemotherapy may be an effective postoperative strategy.

Indexed as

Adenocarcinoma, Clear CellCarcinosarcomaCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedPrognosisRetrospective StudiesSurvival RateUterine NeoplasmsHeterologousHomologousSarcoma dominanceSurvivalUterine carcinosarcoma

Identifiers

PMID30217299
PMCPMC7526039
OpenAlexW2799372610

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.